Alta Partners, of San Francisco, said Edward Penhoet was elected to the Institute of Medicine.
Altea Development Corp., of Atlanta, added Ned Weinshenker to its board.
Amarin Corp. plc, of London, appointed Michael Wess vice president of medical and scientific affairs of Amarin Pharmaceuticals Inc.
Atrix Laboratories Inc., of Fort Collins, Colo., added George Vuturo and Warren Troupe to its board.
Beyond Genomics Inc., of Waltham, Mass., appointed Stephen Naylor chief technology officer.
Bio Syntech Inc., of Laval, Quebec, appointed Alain Geahchan to be responsible for its investor relations.
Biopure Corp., of Cambridge, Mass., added Howard Richman as vice president, regulatory affairs and compliance.
Cellegy Pharmaceuticals Inc., of South San Francisco, appointed Robert Janosky director of marketing.
Cerus Corp., of Concord, Calif., added Bruce Cozadd to its board.
Compugen Ltd., of Princeton, N.J., named Eli Mintz chairman of Compugen Inc., its wholly owned U.S. subsidiary. He is also senior adviser to Compugen.
Cythera Inc., of San Diego, appointed Edward Baetge chief scientific officer.
Deltagen Inc., of Redwood City, Calif., appointed Constantine Anagnostopoulos to its board.
Entomed SA, of Strasbourg, France, appointed Simon Cartmell to its board.
Genset SA, of Paris, appointed Paul Moser vice president of central nervous system development.
Genteric Inc., of Alameda, Calif., appointed Donald Huffman chief financial officer and vice president of finance and administration.
Genzyme Corp., of Cambridge, Mass., named Edward Kaye vice president for medical affairs for lysosomal storage disorders and Hal Landy vice president of clinical research responsible for lysosomal storage disorder therapeutics.
Icagen Inc., of Research Triangle Park, N.C., added Edward Gray as senior vice president, patents and licensing and general patent counsel.
ImClone Systems Inc., of New York, appointed Peter Ringrose, Andrew Bodnar and Peter Peterson to its board.
Insmed Inc., of Richmond, Va., elected Randall Whitcomb to its board.
Integrative Proteomics Inc., of Toronto, appointed Tak Wah Mak to its board.
Isotechnika Inc., of Edmonton, Alberta, appointed Gordon Agopsowicz director of investor relations and corporate communications.
Lipid Sciences Inc., of Pleasanton, Calif., added Jan Johansson as vice president of clinical research and development.
MaxCyte Inc., of Rockville, Md., said its CEO and president, Douglas Doerfler, was elected to the board of directors of the Biotechnology Industry Organization.